Ligand Pharmaceuticals Announces Launch Of Pelthos; Scott Plesha To Assume Leadership Of Pelthos

(RTTNews) - Ligand Pharmaceuticals (LGND) announced the launch of Pelthos Therapeutics, a biopharmaceutical company. Pelthos is a wholly owned subsidiary of Ligand. Pelthos is committed to commercializing therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI is expected to be available in the U.S. in late 2024.

Also, Ligand Pharmaceuticals announced the appointment of Scott Plesha to the role of Chief Executive Officer. Prior to joining Pelthos, Plesha was President and Chief Commercial Officer at BioDelivery Sciences until it was acquired by Collegium Pharmaceutical in 2022.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.